Navigation Links
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
Date:7/21/2009

PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.

These data were presented at the 5th International Conference on HIV Pathogenesis, Treatment and Prevention, held July 19-23, 2009 in Cape Town, South Africa. Both poster presentations can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

    Contact:
    Antoinette Bobbitt, Tobira Therapeutics Inc.
    abobbitt@tobiratherapeutics.com
    Tel: 609-897-1102

www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
3. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Litmus Health , a clinical data ... board. The board comprises leaders spanning business, technology, academia, and pharmaceutical research. The ... Engineering, to Chief Technology Officer. Crooks will lead strategy and development of the ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017   KCNQ2 ... personalized genetic evaluations company, today announced that they ... investigating a genetic mutation implicated in KCNQ2 epileptic ... partnership for a second case involving an additional ... KCNQ2 Cure Alliance and Pairnomix entered into a ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... and biotherapeutics development, announces the launch of a new NTA biosensor chip for ... researchers to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. ...
(Date:7/18/2017)... ... 18, 2017 , ... G-CON today announced that it has ... its Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. ... the protection of G-CON’s R&D investments and validate the G-CON platform as a ...
Breaking Biology Technology:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):